Matsunaga T, Saito H, Kuroda H, Osaki T, et al. CA19-9 in combination with P-CRP as a predictive marker of immune-related adverse
events in patients with recurrent or unresectable advanced gastric cancer treated
with nivolumab. BMC Cancer 2022;22:418.
PMID: 35428212